Cover Image
市場調查報告書

OpportunityAnalyzer:過敏性結膜炎──市場機會分析與未來預測

OpportunityAnalyzer: Allergic Conjunctivitis - Opportunity Analysis and Forecasts to 2018

出版商 GlobalData 商品編碼 320338
出版日期 內容資訊 英文 148 Pages
訂單完成後即時交付
價格
Back to Top
OpportunityAnalyzer:過敏性結膜炎──市場機會分析與未來預測 OpportunityAnalyzer: Allergic Conjunctivitis - Opportunity Analysis and Forecasts to 2018
出版日期: 2014年09月30日 內容資訊: 英文 148 Pages
簡介

過敏性結膜炎的市場,因為很少新產品的上市,過去數年持續穩定的狀態。現在是Dual-Acting產品和皮質類固醇治療藥主導目前的市場,用於急性、慢性過敏結膜炎主要的治療藥。這些醫藥品雖然是有效的治療方法,不過,比那些功效、安全性、可用性高的替代治療選擇仍留有市場機會。預計2018年有3種新藥物上市,預期將帶來超越現有藥物由於專利到期伴隨的經濟損失(更廉價的學名藥的普及等)的效果。治療方法可見到以上的進步,不過,在市場規模方面沒有很大的成長。

本報告提供全球的過敏性結膜炎的治療藥的市場相關分析、疾病概要和目前的治療方法、未滿足需求、市場機會的評估、今後10年的發病數量的預測值、臨床實驗的進展、新開發中產品的評估、今後的市場趨勢等的調查預測,並將結果概述為以下內容。

第1章 目錄

第2章 簡介

第3章 疾病概要

  • 病因與病理學
    • 病因
    • 病理學
    • 預後
    • 生活品質(QoL)
    • 症狀

第4章 流行病學

  • 疾病的背景
  • 危險因素和共生病症
  • 全球趨勢
  • 預測手法
    • 利用之資訊來源
    • 預測的前提條件與手法
  • 過敏性結膜炎的流行病學的預測(今後11年分)
    • 過敏性結膜炎的總患者數
    • 過敏性結膜炎的總患者數:各年齡
    • 過敏性結膜炎的總患者數:男女
  • 討論
    • 流行病學預測相關考察
    • 分析的限制
    • 分析的優勢

第5章 目前治療方法的選項:概要

  • 產品簡介:領導品牌
    • 抗組織胺藥
    • 肥大細胞穩定劑
    • Dual-Acting產品
    • Pataday
    • Elestat
    • Bepreve
    • Lastacaft
    • 非類固醇消炎劑
    • 皮質類固醇
    • Lotemax
    • Durezol
    • 免疫抑製藥

第6章 未滿足需求評估及機會分析

  • 概要
  • 未滿足需求分析
    • 未滿足需求:長期使用的更安全的皮質類固醇
    • 未滿足需求:更高功效的醫藥品
    • 未滿足需求:醫生、患者對過敏性結膜炎的認識擴大
  • 機會分析
    • 機會:以過敏性結膜炎的亞型為目標的有效治療方法
    • 機會:改善副作用特性的藥物

第7章 研究開發策略

  • 概要
    • 現有的治療方法的改良
    • 著重利基患者
    • 新等級的治療方法的發展
    • 臨床試驗設計
    • 臨床實驗的設計
    • 臨床實驗參加者的募集
    • 未來臨床實驗的設計

第8章 開發平台評估

  • 概要
  • 臨床開發階段的有潛力的藥劑
    • Vekacia
    • 太陽1334H(抗組織胺藥)
    • OTX-DP
    • RX-10045
    • AC-170
  • 初期階段的創新方法

第9章 開發中產品的評估分析

  • 主要開發平台醫藥品臨床方面的比較分析
  • 主要開發平台醫藥品的商用方面的比較分析
  • 競爭分析
  • 今後5年的銷售額預測
    • 美國
    • EU5個國家

第10章 附錄

圖表一覽

目錄
Product Code: GDHC030POA

The allergic conjunctivitis market has remained relatively static over the last few years, due to a limited number of new products. It is currently dominated by dual-acting products and corticosteroid therapies, which form the core treatment options for both acute and chronic allergic conjunctivitis sufferers. Although these therapies provide effective treatment regimens, there are opportunities for the development of alternative treatment choices, improvements in efficacy, safety and compliance. By 2018, there will be three new entrants to the allergic conjunctivitis market. These new products will help drive market growth and offset the impending patent expiries of the majority of the remaining brands (Lotemax, Patanol and Lastacaft) during the forecast period, which will permit the entry of inexpensive generics. Despite these advancements in the treatment landscape, the allergic conjunctivitis market is not expected to experience a noticeable change in terms of growth.

Highlights

Key Questions Answered

  • The allergic conjunctivitis market is marked by the presence of a number of unmet needs in current treatments. What are the main unmet needs in this market Will the drugs under development fulfil the unmet needs of the allergic conjunctivitis market
  • The late-stage allergic conjunctivitis pipeline consists of a new class of therapy, reformulation of existing, non-approved therapies and a therapy with a novel route of administration. Which drug will have a significant impact on the allergic conjunctivitis market Which of these drugs will have the highest CAGR, and why
  • The allergic conjunctivitis market is currently dominated by generic drugs. How will the introduction of new therapies change the treatment landscape How will the drug treatment rates change over the next five years What are the key drivers and barriers to this change

Key Findings

  • The main driver of the expansion of the allergic conjunctivitis market will be the introduction of three new therapies across the 6 major markets.
  • The biggest barrier for the introduction of new therapies will be patent expirations of the majority of the drugs marketed for allergic conjunctivitis, which will result in an increase of generics, and which may negatively impact revenue from branded drugs that are expected to launch in the forecast period.
  • The concerns of reducing healthcare costs as part of government austerity measures, particularly in Europe, which will impede market growth. To ensure reimbursement companies will have to work closely together with payers and price their drugs competitively.

Scope

  • Overview of allergic conjunctivitis, including epidemiology, etiology, pathophysiology, symptoms, diagnosis, and treatment guidelines.
  • Annualized allergic conjunctivitis therapeutics market revenue, annual cost of therapy and treatment usage pattern data from 2013 and forecast for five years to 2018.
  • Key topics covered include market characterization, unmet needs, R&D and clinical trials assessment, late stage clinical trial analysis and implications for the allergic conjunctivitis therapeutics market.
  • Pipeline analysis: focus on the five late-stage pipeline drugs discussing emerging trends as well as overview of earlier phase drugs.
  • Analysis of the current and future market competition in the global allergic conjunctivitis therapeutics market. Insightful review of the key industry drivers, restraints and challenges. Each trend is independently researched to provide qualitative analysis of its implications.

Reasons to buy

  • Develop and design your in-licensing and out-licensing strategies through a review of pipeline products and technologies, and by identifying the companies with the most robust pipeline.
  • Additionally a list of acquisition targets included in the pipeline product company list.
  • Develop business strategies by understanding the trends shaping and driving the global allergic conjunctivitis therapeutics market.
  • Drive revenues by understanding the key trends, innovative products and technologies, market segments, and companies likely to impact the global allergic conjunctivitis therapeutics market in future.
  • Formulate effective sales and marketing strategies by understanding the competitive landscape and by analysing the performance of various competitors.
  • Identify emerging players with potentially strong product portfolios and create effective counter-strategies to gain a competitive advantage.
  • Track drug sales in the global allergic conjunctivitis therapeutics market from 2013-2018.
  • Organize your sales and marketing efforts by identifying the market categories and segments that present maximum opportunities for consolidations, investments and strategic partnerships.

Table of Contents

1. Table of Contents

  • 1.1. List of Tables
  • 1.2. List of Figures

2. Introduction

  • 2.1. Catalyst
  • 2.2. Related Reports
  • 2.3. Upcoming Related Reports

3. Disease Overview

  • 3.1. Etiology and Pathophysiology
    • 3.1.1. Etiology
    • 3.1.2. Pathophysiology
    • 3.1.3. Prognosis
    • 3.1.4. Quality of Life
    • 3.1.5. Symptoms

4. Epidemiology

  • 4.1. Disease Background
  • 4.2. Risk Factors and Comorbidities
  • 4.3. Global Trends
  • 4.4. Forecast Methodology
    • 4.4.1. Sources Used
    • 4.4.2. Forecast Assumptions and Methods
  • 4.5. Epidemiological Forecast for Allergic Conjunctivitis (2013-2023)
    • 4.5.1. Total Prevalent Cases of Allergic Conjunctivitis
    • 4.5.2. Age-Specific Total Prevalent Cases of Allergic Conjunctivitis
    • 4.5.3. Sex-Specific Total Prevalent Cases of Allergic Conjunctivitis
  • 4.6. Discussion
    • 4.6.1. Epidemiological Forecast Insight
    • 4.6.2. Limitations of the Analysis
    • 4.6.3. Strengths of the Analysis

5. Current Treatment Options Overview

  • 5.1. Product Profiles - Major Brands
    • 5.1.1. Antihistamines
    • 5.1.2. Mast Cell Stabilizers
    • 5.1.3. Dual-Acting Products
    • 5.1.4. Pataday (olopatadine)
    • 5.1.5. Elestat (epinastine)
    • 5.1.6. Bepreve (bepotastine)
    • 5.1.7. Lastacaft (alcaftadine)
    • 5.1.8. Nonsteroidal Anti-Inflammatory Drugs
    • 5.1.9. Corticosteroids
    • 5.1.10. Lotemax (loteprednol etabonate)
    • 5.1.11. Durezol (difluprednate)
    • 5.1.12. Immunosuppressants

6. Unmet Needs Assessment and Opportunity Analysis

  • 6.1. Overview
  • 6.2. Unmet Needs Analysis
    • 6.2.1. Unmet Need: Safer Corticosteroids for Long-Term Use
    • 6.2.2. Unmet Need: More Efficacious Medicines
    • 6.2.3. Unmet Need: Increased Physician and Patient Awareness of Allergic Conjunctivitis
  • 6.3. Opportunity Analysis
    • 6.3.1. Opportunity: Effective Therapies that Would Target Allergic Conjunctivitis Subtypes
    • 6.3.2. Opportunity: Drugs With an Improved Side Effect Profile

7. Research and Development Strategies

  • 7.1. Overview
    • 7.1.1. Reformulations of the Existing Therapies
    • 7.1.2. Focus on Niche Patient Subgroups
    • 7.1.3. Development of Novel Classes of Therapies
    • 7.1.4. Clinical Trial Design
    • 7.1.5. Trial Design
    • 7.1.6. Recruiting Trial Participants
    • 7.1.7. Future Trial Design

8. Pipeline Assessment

  • 8.1. Overview
  • 8.2. Promising Drugs in Clinical Development
    • 8.2.1. Vekacia (cyclosporine)
    • 8.2.2. SUN-1334H (antihistamine)
    • 8.2.3. OTX-DP (dexamethasone)
    • 8.2.4. RX-10045 (resolvin)
    • 8.2.5. AC-170 (cetirizine)
  • 8.3. Innovative Early-Stage Approaches

9. Pipeline Valuation Analysis

  • 9.1. Clinical Benchmarking of Key Pipeline Drugs
  • 9.2. Commercial Benchmark of Key Pipeline Drugs
  • 9.3. Competitive Assessment
  • 9.4. Top-Line Five-Year Forecast
    • 9.4.1. US
    • 9.4.2. 5EU

10. Appendix

  • 10.1. Bibliography
  • 10.2. Abbreviations
  • 10.3. Methodology
  • 10.4. Forecasting Methodology
    • 10.4.1. Diagnosed Allergic Conjunctivitis Patients
    • 10.4.2. Percentage of Drug-Treated Patients
    • 10.4.3. Drugs Included in Each Therapeutic Class
    • 10.4.4. Launch Dates
    • 10.4.5. General Pricing Assumptions
    • 10.4.6. Individual Drug Assumptions
    • 10.4.7. Generic Erosion
    • 10.4.8. Pricing of Pipeline Agents
  • 10.5. Physicians and Specialists Included in this Study
  • 10.6. About the Authors
    • 10.6.1. Authors
    • 10.6.2. Reviewer
    • 10.6.3. Epidemiologist
    • 10.6.4. Global Head of Healthcare
  • 10.7. About GlobalData
  • 10.8. Disclaimer

List of Tables

  • Table 1: Characteristics of Allergic Conjunctivitis Subtypes
  • Table 2: Risk Factors and Comorbidities for Allergic Conjunctivitis
  • Table 3: 6MM, Sources of Allergic Conjunctivitis Prevalence Data Used in the Epidemiology Forecast
  • Table 4: 6MM, Total Prevalent Cases of Allergic Conjunctivitis, All Ages, Both Sexes, N, 2013-2023
  • Table 5: 6MM, Total Prevalent Cases of Allergic Conjunctivitis, by Age, Both Sexes, N (Row %), 2013
  • Table 6: 6MM, Total Prevalent Cases of Allergic Conjunctivitis, by Sex, All Ages, N (Row %), 2013
  • Table 7: Leading Treatments for Allergic Conjunctivitis
  • Table 8: Product Profile -Antihistamines
  • Table 9: Antihistamines SWOT Analysis
  • Table 10: Product Profile - Mast Cell Stabilizers
  • Table 11: Mast Cell Stabilizers SWOT Analysis
  • Table 12: Product Profile - Dual-Acting Products
  • Table 13: Dual-Acting Products, SWOT Analysis
  • Table 14: Pataday SWOT Analysis
  • Table 15: Elestat SWOT Analysis
  • Table 16: Bepreve SWOT Analysis
  • Table 17: Lastacaft SWOT Analysis
  • Table 18: Product Profile - NSAIDs
  • Table 19: Topical Ocular NSAIDs SWOT Analysis
  • Table 20: Product Profile - Corticosteroids
  • Table 21: Corticosteroids SWOT Analysis
  • Table 22: Lotemax and Alrex SWOT Analysis
  • Table 23: Durezol SWOT Analysis
  • Table 24: Product Profile - Restasis
  • Table 25: Restasis SWOT Analysis
  • Table 26: Overall Unmet Needs - Current Levels of Attainment
  • Table 27: Allergic Conjunctivitis - Late-Stage Pipeline, 2014
  • Table 28: Product Profile - Vekacia
  • Table 29: Vekacia SWOT Analysis
  • Table 30: Product Profile - SUN-1334H
  • Table 31: SUN-1334H SWOT Analysis
  • Table 32: Product Profile - OTX-DP
  • Table 33: OTX-DP SWOT Analysis
  • Table 34: Product Profile - RX-10045
  • Table 35: RX-10045 SWOT Analysis
  • Table 36: Product Profile - AC-170
  • Table 37: AC-170 SWOT Analysis
  • Table 38: Early-Stage Pipeline Products for Allergic Conjunctivitis
  • Table 39: Clinical Benchmarking of Key Pipeline Drugs-Allergic Conjunctivitis First-Line
  • Table 40: Clinical Benchmarking of Key Pipeline Drugs-Allergic Conjunctivitis Second-Line
  • Table 41: Commercial Benchmark of Key Pipeline Drugs-Allergic Conjunctivitis First-Line
  • Table 42: Commercial Benchmark of Key Pipeline Drugs-Allergic Conjunctivitis Second-Line
  • Table 43: Top-Line Sales Forecasts ($) for Allergic Conjunctivitis, 2013-2018
  • Table 44: Key Events Impacting Sales of Allergic Conjunctivitis Therapies, 2013-2018
  • Table 45 Allergic Conjunctivitis- Drivers and Barriers, US and EU
  • Table 46: Key Launch Dates

List of Figures

  • Figure 1: Allergic Inflammatory Response
  • Figure 2: 6MM, Total Prevalent Cases of Allergic Conjunctivitis, All Ages, Both Sexes, N, 2013-2023
  • Figure 3: 6MM, Total Prevalent Cases of Allergic Conjunctivitis, by Age, Both Sexes, N, 2013-2023
  • Figure 4: 6MM, Total Prevalent Cases of Allergic Conjunctivitis, by Sex, All Ages, N, 2013
  • Figure 5: Competitive Assessment of Late-Stage Pipeline Agents in Allergic Conjunctivitis- First-Line, 2013-2018
  • Figure 6: Competitive Assessment of Late-Stage Pipeline Agents in Allergic Conjunctivitis- Second-Line, 2013-2018
  • Figure 7: Global Sales for Allergic Conjunctivitis by Region, 2013-2018
Back to Top